Dr. Barbara Burtness, M.D., is a Professor of Medicine (Medical Oncology) at the Yale School of Medicine and Yale Cancer Center. She serves as Co-Leader of the Developmental Therapeutics Program and the Disease Aligned Research Team Leader for Head and Neck Cancer. She also chairs the ECOG-ACRIN Oncology Group Head and Neck Cancer Therapeutics Committee. Dr Burtness received her M.D. with distinction from SUNY at Stony Brook. She completed her internship and residency at Yale-New Haven Hospital and fellowship training in oncology at the Memorial Sloan Kettering Cancer Center.

Dr. Burtness is internationally renowned for her clinical expertise in multiple early and late phase immunotherapy trials for head and neck cancer. Specifically, her research studies biomarkers of resistance to immunotherapy and EGFR inhibition as well as novel strategies in EGFR targeting. Additionally, she has served as the principal investigator for multiple pivotal studies that have led to the successful commercialization of breakthrough targeted therapies. Notably, she led the KEYNOTE-048 pivotal study that moved pembrolizumab into first-line for the treatment of advanced head and neck squamous cell carcinoma (HNSCC).